Shares Magazine
1.55p+0.17 (+12.73%)18 Nov 2024, 16:09
Jump to:
Valirx PLC Fundamentals
| Company Name | Valirx PLC | Last Updated | 2024-11-18 |
|---|---|---|---|
| Industry | Biotechnology | Sector | Healthcare |
| Shares in Issue | 132.349 m | Market Cap | £2.05 m |
| PE Ratio | 0.00 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -£0.02 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0.0046 | Debt Equity Ratio | 0.0017 |
| Asset Equity Ratio | 1.0536 | Cash Equity Ratio | 0.2309 |
| Quick Ratio | 5.0169 | Current Ratio | 6.65 |
| Price To Book Value | 0.4729 | ROCE | 0 |
Valirx PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Valirx PLC Company Financials
| Assets | 2023 | 2022 | 2021 |
|---|---|---|---|
| Tangible Assets | £242,625.00 | £5,561.00 | £13,278.00 |
| Intangible Assets | £2.32 m | £2.51 m | £2.71 m |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | £2.56 m | £2.51 m | £2.72 m |
| Stocks | £69,002.00 | 0 | 0 |
| Debtors | £99,050.00 | £76,228.00 | £66,122.00 |
| Cash & Equivalents | £174,684.00 | £1.14 m | £593,672.00 |
| Other Assets | 0 | 0 | 0 |
| Total Assets | £3.13 m | £3.98 m | £3.52 m |
| Liabilities | 2023 | 2022 | 2021 |
|---|---|---|---|
| Creditors within 1 year | £214,654.00 | £127,575.00 | £68,220.00 |
| Creditors after 1 year | £11,857.00 | £22,070.00 | £41,335.00 |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £226,511.00 | £149,645.00 | £109,555.00 |
| Net assets | £2.90 m | £3.83 m | £3.41 m |
| Equity | 2023 | 2022 | 2021 |
|---|---|---|---|
| Called up share capital | £102,320.00 | £90,174.00 | £65,049.00 |
| Share Premium | £27.87 m | £26.77 m | £24.49 m |
| Profit / Loss | -£2.30 m | -£2.60 m | -£1.68 m |
| Other Equity | £3.22 m | £4.05 m | £3.60 m |
| Preference & Minorities | -£314,623.00 | -£224,539.00 | -£184,867.00 |
| Total Capital Employed | £2.90 m | £3.83 m | £3.41 m |
| Ratios | 2023 | 2022 | 2021 |
|---|---|---|---|
| Debt Ratio | £0.00 | £0.01 | £0.01 |
| Debt-to-Equity | £0.00 | £0.01 | £0.01 |
| Assets / Equity | 1.0536 | 1.0536 | 1.0536 |
| Cash / Equity | 0.2309 | 0.2309 | 0.2309 |
| EPS | -£0.02 | -£0.03 | -£0.02 |
| Cash Flow | 2023 | 2022 | 2021 |
|---|---|---|---|
| Cash from operating activities | -£1.77 m | -£1.71 m | -£1.26 m |
| Cashflow before financing | -£656,612.00 | £543,805.00 | -£1.25 m |
| Increase in Cash | -£962,793.00 | £543,805.00 | -£1.25 m |
| Income | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | £9,600.00 | 0 | 0 |
| Cost of sales | £1,440.00 | 0 | 0 |
| Gross Profit | £8,160.00 | 0 | 0 |
| Operating Profit | -£2.30 m | -£2.59 m | -£1.68 m |
| Pre-Tax profit | -£2.30 m | -£2.60 m | -£1.68 m |
Valirx PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers,specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, VAL401 for lung cancer, VAL301, BC201, CLX001, and other drug candidates in their different stages of development. |
| Latest Interim Date | 27 Sep 2024 |
| Latest Fiscal Year End Date | 15 May 2024 |
Valirx PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2013-10-08 | Mr. James Nicholas Thorniley | Non-Executive Director,Chairman |
| 2020-04-14 | Dr. George Morris | Executive Director,Chief Operating Officer |
| 2020-04-14 | Dr. Satu Vainikka | Executive Director,Chief Executive Officer |
| 2024-05-15 | Mr. Gerald Desler | Executive Director,Chief Financial Officer and Company Secretary |
| 2022-06-30 | Mr. Kevin J Alexander | Non-Executive Director,Company Secretary |
| 2010-04-01 | Dr. Jacob Micallef | Executive Director,Chief Technical Officer |
| 2024-04-15 | Ms. Stella Panu | Non-Executive Director |
| 2007-10-25 | Mr. Anthony Roger Moore | Non-Executive Director,Chairman |
| 2020-07-03 | Mr. Oliver de Giorgio-Miller | Non-Executive Director,Chairman |
| 2024-08-12 | Dr. Mark Edward Eccleston | Executive Director,Chief Executive Officer |
| 2019-05-31 | Mr. Seppo Olavi Makinen | Non-Executive Director |
| 2024-10-18 | Mr. Martin Lampshire | Non-Executive Director |
| 2024-08-15 | Dr. Suzanne Dilly | Executive Director |
| 2024-06-19 | Dr. Kevin Paul Cox | Non-Executive Director,Chairman |
| 2024-04-22 | Mr. Adrian Michael Patrick de Courcey | Non-Executive Director |
| 2024-07-25 | Ms. Catherine Jane Tralau-Stewart | Executive Director,Chief Scientific Officer |
Valirx PLC Contact Details
| Company Name | ValiRx PLC |
|---|---|
| Address | 16 Upper Woburn Place, London, WC1H 0BS |
| Telephone | +44 2030084416 |
| Website | https://www.valirx.com |
Valirx PLC Advisors
| Stockbroker | Beaufort Securities Ltd |
|---|---|
| Phone | +44 2073828300 |
| Fax | +44 2073828400 |
| Solicitor | Pinsent Masons LLP |
|---|---|
| Phone | +44 2074187000 |
| Fax | +44 2074187050 |
| Auditor | Adler Shine LLP |
|---|---|
| Phone | +44 2083713000 |
| Fax | +44 2083713099 |
| Bank | Royal Bank of Scotland PLC |
|---|
| Financial PR Adviser | Peckwater PR |
|---|
| Registrar | Capita Asset Services |
|---|---|
| Phone | +44 8704027573 |
| Nominated Adviser | Cairn Financial Advisers LLP |
|---|---|
| Phone | +44 2072130880 |
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
